Marine v-3 polyunsaturated fatty acid and fish intake after colon cancer diagnosis and survival

CALGB 89803 (Alliance)

Erin L. Van Blarigan*, Charles S. Fuchs, Donna Niedzwiecki, Xing Ye, Sui Zhang, Mingyang Song, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al B Benson III, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Edward L. Giovannucci, Jeffrey A. Meyerhardt

*Corresponding author for this work

Research output: Contribution to journalEditorial

12 Citations (Scopus)

Abstract

Background: Marine w-3 polyunsaturated fatty acids (PUFAs), primarily found in dark fish, may prevent colorectal cancer progression, in part through inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2). However, data in humans are limited. Methods: We examined marine w-3 PUFAs and fish intake and survival among 1,011 colon cancer patients enrolled in Cancer and Leukemia Group B 89803 between 1999 and 2001 and followed through 2009. Diet was assessed during and 6 months after chemotherapy. We used Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for disease-free (DFS), recurrence-free (RFS), and overall survival (OS). Results: We observed 343 recurrences and 305 deaths (median follow-up: 7 years). Patients in the highest vs. lowest quartile of marine w-3 PUFA intake had an HR for DFS of 0.72 (95% CI, 0.54–0.97; Ptrend ¼ 0.03). Individuals who consumed dark fish 1/week versus never had longer DFS (HR 0.65; 95% CI, 0.48–0.87; P-value ¼ 0.007), RFS (HR 0.61; 95% CI, 0.46–0.86; Ptrend ¼ 0.007), and OS (HR 0.68; 95% CI, 0.48–0.96; Ptrend ¼ 0.04). In a subset of 510 patients, the association between marine w-3 PUFA intake and DFS appeared stronger in patients with high PTGS2 expression (HR 0.32; 95% CI, 0.11–0.95; Ptrend ¼ 0.01) compared with patients with absent/low PTGS2 expression (HR 0.78; 95% CI, 0.48–1.27; Ptrend ¼ 0.35; Pinteraction ¼ 0.19). Conclusions: Patients with high intake of marine w-3 PUFAs and dark fish after colon cancer diagnosis may have longer DFS.

Original languageEnglish (US)
Pages (from-to)438-445
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume27
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Unsaturated Fatty Acids
Colonic Neoplasms
Fishes
Confidence Intervals
Survival
Prostaglandin-Endoperoxide Synthases
Recurrence
Colorectal Neoplasms
Leukemia
Diet
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Van Blarigan, Erin L. ; Fuchs, Charles S. ; Niedzwiecki, Donna ; Ye, Xing ; Zhang, Sui ; Song, Mingyang ; Saltz, Leonard B. ; Mayer, Robert J. ; Mowat, Rex B. ; Whittom, Renaud ; Hantel, Alexander ; Benson III, Al B ; Atienza, Daniel ; Messino, Michael ; Kindler, Hedy ; Venook, Alan ; Ogino, Shuji ; Giovannucci, Edward L. ; Meyerhardt, Jeffrey A. / Marine v-3 polyunsaturated fatty acid and fish intake after colon cancer diagnosis and survival : CALGB 89803 (Alliance). In: Cancer Epidemiology Biomarkers and Prevention. 2018 ; Vol. 27, No. 4. pp. 438-445.
@article{dec7a683557948f1b1b7e9dbd876225a,
title = "Marine v-3 polyunsaturated fatty acid and fish intake after colon cancer diagnosis and survival: CALGB 89803 (Alliance)",
abstract = "Background: Marine w-3 polyunsaturated fatty acids (PUFAs), primarily found in dark fish, may prevent colorectal cancer progression, in part through inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2). However, data in humans are limited. Methods: We examined marine w-3 PUFAs and fish intake and survival among 1,011 colon cancer patients enrolled in Cancer and Leukemia Group B 89803 between 1999 and 2001 and followed through 2009. Diet was assessed during and 6 months after chemotherapy. We used Cox proportional hazards regression to estimate hazard ratios (HRs) and 95{\%} confidence intervals (CIs) for disease-free (DFS), recurrence-free (RFS), and overall survival (OS). Results: We observed 343 recurrences and 305 deaths (median follow-up: 7 years). Patients in the highest vs. lowest quartile of marine w-3 PUFA intake had an HR for DFS of 0.72 (95{\%} CI, 0.54–0.97; Ptrend ¼ 0.03). Individuals who consumed dark fish 1/week versus never had longer DFS (HR 0.65; 95{\%} CI, 0.48–0.87; P-value ¼ 0.007), RFS (HR 0.61; 95{\%} CI, 0.46–0.86; Ptrend ¼ 0.007), and OS (HR 0.68; 95{\%} CI, 0.48–0.96; Ptrend ¼ 0.04). In a subset of 510 patients, the association between marine w-3 PUFA intake and DFS appeared stronger in patients with high PTGS2 expression (HR 0.32; 95{\%} CI, 0.11–0.95; Ptrend ¼ 0.01) compared with patients with absent/low PTGS2 expression (HR 0.78; 95{\%} CI, 0.48–1.27; Ptrend ¼ 0.35; Pinteraction ¼ 0.19). Conclusions: Patients with high intake of marine w-3 PUFAs and dark fish after colon cancer diagnosis may have longer DFS.",
author = "{Van Blarigan}, {Erin L.} and Fuchs, {Charles S.} and Donna Niedzwiecki and Xing Ye and Sui Zhang and Mingyang Song and Saltz, {Leonard B.} and Mayer, {Robert J.} and Mowat, {Rex B.} and Renaud Whittom and Alexander Hantel and {Benson III}, {Al B} and Daniel Atienza and Michael Messino and Hedy Kindler and Alan Venook and Shuji Ogino and Giovannucci, {Edward L.} and Meyerhardt, {Jeffrey A.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1158/1055-9965.EPI-17-0689",
language = "English (US)",
volume = "27",
pages = "438--445",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

Van Blarigan, EL, Fuchs, CS, Niedzwiecki, D, Ye, X, Zhang, S, Song, M, Saltz, LB, Mayer, RJ, Mowat, RB, Whittom, R, Hantel, A, Benson III, AB, Atienza, D, Messino, M, Kindler, H, Venook, A, Ogino, S, Giovannucci, EL & Meyerhardt, JA 2018, 'Marine v-3 polyunsaturated fatty acid and fish intake after colon cancer diagnosis and survival: CALGB 89803 (Alliance)', Cancer Epidemiology Biomarkers and Prevention, vol. 27, no. 4, pp. 438-445. https://doi.org/10.1158/1055-9965.EPI-17-0689

Marine v-3 polyunsaturated fatty acid and fish intake after colon cancer diagnosis and survival : CALGB 89803 (Alliance). / Van Blarigan, Erin L.; Fuchs, Charles S.; Niedzwiecki, Donna; Ye, Xing; Zhang, Sui; Song, Mingyang; Saltz, Leonard B.; Mayer, Robert J.; Mowat, Rex B.; Whittom, Renaud; Hantel, Alexander; Benson III, Al B; Atienza, Daniel; Messino, Michael; Kindler, Hedy; Venook, Alan; Ogino, Shuji; Giovannucci, Edward L.; Meyerhardt, Jeffrey A.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 27, No. 4, 01.04.2018, p. 438-445.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - Marine v-3 polyunsaturated fatty acid and fish intake after colon cancer diagnosis and survival

T2 - CALGB 89803 (Alliance)

AU - Van Blarigan, Erin L.

AU - Fuchs, Charles S.

AU - Niedzwiecki, Donna

AU - Ye, Xing

AU - Zhang, Sui

AU - Song, Mingyang

AU - Saltz, Leonard B.

AU - Mayer, Robert J.

AU - Mowat, Rex B.

AU - Whittom, Renaud

AU - Hantel, Alexander

AU - Benson III, Al B

AU - Atienza, Daniel

AU - Messino, Michael

AU - Kindler, Hedy

AU - Venook, Alan

AU - Ogino, Shuji

AU - Giovannucci, Edward L.

AU - Meyerhardt, Jeffrey A.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Marine w-3 polyunsaturated fatty acids (PUFAs), primarily found in dark fish, may prevent colorectal cancer progression, in part through inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2). However, data in humans are limited. Methods: We examined marine w-3 PUFAs and fish intake and survival among 1,011 colon cancer patients enrolled in Cancer and Leukemia Group B 89803 between 1999 and 2001 and followed through 2009. Diet was assessed during and 6 months after chemotherapy. We used Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for disease-free (DFS), recurrence-free (RFS), and overall survival (OS). Results: We observed 343 recurrences and 305 deaths (median follow-up: 7 years). Patients in the highest vs. lowest quartile of marine w-3 PUFA intake had an HR for DFS of 0.72 (95% CI, 0.54–0.97; Ptrend ¼ 0.03). Individuals who consumed dark fish 1/week versus never had longer DFS (HR 0.65; 95% CI, 0.48–0.87; P-value ¼ 0.007), RFS (HR 0.61; 95% CI, 0.46–0.86; Ptrend ¼ 0.007), and OS (HR 0.68; 95% CI, 0.48–0.96; Ptrend ¼ 0.04). In a subset of 510 patients, the association between marine w-3 PUFA intake and DFS appeared stronger in patients with high PTGS2 expression (HR 0.32; 95% CI, 0.11–0.95; Ptrend ¼ 0.01) compared with patients with absent/low PTGS2 expression (HR 0.78; 95% CI, 0.48–1.27; Ptrend ¼ 0.35; Pinteraction ¼ 0.19). Conclusions: Patients with high intake of marine w-3 PUFAs and dark fish after colon cancer diagnosis may have longer DFS.

AB - Background: Marine w-3 polyunsaturated fatty acids (PUFAs), primarily found in dark fish, may prevent colorectal cancer progression, in part through inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2). However, data in humans are limited. Methods: We examined marine w-3 PUFAs and fish intake and survival among 1,011 colon cancer patients enrolled in Cancer and Leukemia Group B 89803 between 1999 and 2001 and followed through 2009. Diet was assessed during and 6 months after chemotherapy. We used Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for disease-free (DFS), recurrence-free (RFS), and overall survival (OS). Results: We observed 343 recurrences and 305 deaths (median follow-up: 7 years). Patients in the highest vs. lowest quartile of marine w-3 PUFA intake had an HR for DFS of 0.72 (95% CI, 0.54–0.97; Ptrend ¼ 0.03). Individuals who consumed dark fish 1/week versus never had longer DFS (HR 0.65; 95% CI, 0.48–0.87; P-value ¼ 0.007), RFS (HR 0.61; 95% CI, 0.46–0.86; Ptrend ¼ 0.007), and OS (HR 0.68; 95% CI, 0.48–0.96; Ptrend ¼ 0.04). In a subset of 510 patients, the association between marine w-3 PUFA intake and DFS appeared stronger in patients with high PTGS2 expression (HR 0.32; 95% CI, 0.11–0.95; Ptrend ¼ 0.01) compared with patients with absent/low PTGS2 expression (HR 0.78; 95% CI, 0.48–1.27; Ptrend ¼ 0.35; Pinteraction ¼ 0.19). Conclusions: Patients with high intake of marine w-3 PUFAs and dark fish after colon cancer diagnosis may have longer DFS.

UR - http://www.scopus.com/inward/record.url?scp=85045520458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045520458&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-17-0689

DO - 10.1158/1055-9965.EPI-17-0689

M3 - Editorial

VL - 27

SP - 438

EP - 445

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 4

ER -